Valneva SE (VLA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Valneva SE (Valneva) is a biotech company that develops lifesaving vaccines. The companys products include IXIARO, a vaccine indicated for the prevention of Japanese encephalitis; and Dukoral, a vaccine indicated for the prevention of cholera and diarrhea; clostridium difficile, lyme, chikungunya, and zika diseases. It provides EB66 cell line, a proprietary embryonic stem cell-based technology which is used for the production of human and veterinary viral and therapeutic vaccines; and IC31, a synthetic vaccine adjuvant. Valneva partners with pharmaceutical and biotech companies to develop products using its proprietary technologies. The company operates in Austria, Sweden, the UK, France, Canada, and the US. Valneva is headquartered in Lyon, France.

Valneva SE (VLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 5
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Valneva SE, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Valneva SE, Medical Devices Deals, 2012 to YTD 2018 10
Valneva SE, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Valneva SE, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Valneva to Secure USD18 Million from Funds Managed by Athyrium 13
BliNK Biomedical Raises Funds through Series A Venture Financing 14
Valneva Austria Raises US$30 Million In Venture Financing 15
Private Equity 16
Valneva Raises USD8 Million in First Tranche of Private Equity Investment 16
Partnerships 17
InFlectis BioScience Enters into Licensing Agreement with Valneva 17
Seqirus Enters into Distribution Agreement with Valneva 18
Valneva Enters into R&D Agreement with GlaxoSmithKline 19
Valneva Enters into Distribution Agreement with PaxVax 20
PaxVax Enters into Distribution Agreement with Valneva 21
Valneva Forms Joint Venture with BliNK Therapeutics 22
Licensing Agreements 23
Emergent BioSolutions Enters into Licensing Agreement with Valneva 23
Bavarian Nordic Enters into Licensing Agreement with Valneva 24
Valneva Enters into Licensing Agreement with Jianshun Biosciences 25
Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 26
Valneva Enters into Licensing Agreement with Adimmune for Japanese Encephalitis Vaccine 27
Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 28
Valneva to Enter into Licensing Agreement with Pharma Company 29
Valneva to Enter into Licensing Agreement with Japan-Based Animal Vaccine Manufacturer 30
GeoVax Labs Enters into Licensing Agreement with Valneva 31
Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine 32
Equity Offering 33
Valneva Raises USD54 Million in Rights Offering 33
Valneva Completes Rights Offering Of Shares For US$53.5 Million 35
Asset Transactions 37
Valneva Sells Clinical Manufacturing Operations Facility To Biological E 37
Acquisition 38
Valneva Acquires Crucell Sweden for USD54 Million 38
Valneva SE - Key Competitors 39
Valneva SE - Key Employees 40
Valneva SE - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 43
Financial Announcements 43
Aug 02, 2018: VALNEVA Delivers Strong IXIARO Sales Growth and reports Further Progress on Key R&D Programs in H1 43
May 17, 2018: VALNEVA Reports Strong Q1 Results and Continues to Advance Key R&D Programs 47
Mar 22, 2018: VALNEVA Delivers Strong 2017 Financial Results and Advances Key R&D Programs 50
Nov 09, 2017: Valneva Reports Strong Operational Performance for the First Nine Months of 2017 54
Aug 31, 2017: Valneva Reports Robust H1 2017 Financial Results & Major R&D Progress 55
May 11, 2017: VALNEVA Reports Strong Q1 Revenue Growth and Positive EBITDA; Reaffirms Financial Guidance and Pipeline Outlook for 2017 60
Mar 23, 2017: VALNEVA Reports Best Financial Results in the Companys History with its First Year of Positive EBITDA in 2016 63
Feb 23, 2017: VALNEVA Reports Strong Q4 and FY 2016 Business Performance; Expects Further Growth in Sales and EBITDA, R&D Progress in 2017 68
Corporate Communications 71
Jun 29, 2018: VALNEVA Announces Successful Outcome of its AGM and Renewal of the Term of Office of its Management Board Members 71
Aug 01, 2017: VALNEVA Announces Expansion of its Management Board - Strengthening Senior Management for Future Growth 72
Product News 73
Apr 10, 2017: Valneva to Present at the 17th World Vaccine Congress in Washington D.C. 73
Clinical Trials 74
Mar 29, 2018: VALNEVA to Present Data on VLA-1601 at the 18th World Vaccine Congress in Washington, D.C. 74
Feb 26, 2018: Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus 75
Other Significant Developments 76
Dec 11, 2017: Intercell USA Changes Name to Valneva USA and Expands Commercial Presence 76
Jun 30, 2017: Valneva Announces Successful Outcome of its AGM and the Appointment of two new Supervisory Board Members 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78

List Of Tables


Valneva SE, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Valneva SE, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Valneva SE, Deals By Therapy Area, 2012 to YTD 2018 9
Valneva SE, Medical Devices Deals, 2012 to YTD 2018 10
Valneva SE, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Valneva to Secure USD18 Million from Funds Managed by Athyrium 13
BliNK Biomedical Raises Funds through Series A Venture Financing 14
Valneva Austria Raises US$30 Million In Venture Financing 15
Valneva Raises USD8 Million in First Tranche of Private Equity Investment 16
InFlectis BioScience Enters into Licensing Agreement with Valneva 17
Seqirus Enters into Distribution Agreement with Valneva 18
Valneva Enters into R&D Agreement with GlaxoSmithKline 19
Valneva Enters into Distribution Agreement with PaxVax 20
PaxVax Enters into Distribution Agreement with Valneva 21
Valneva Forms Joint Venture with BliNK Therapeutics 22
Emergent BioSolutions Enters into Licensing Agreement with Valneva 23
Bavarian Nordic Enters into Licensing Agreement with Valneva 24
Valneva Enters into Licensing Agreement with Jianshun Biosciences 25
Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 26
Valneva Enters into Licensing Agreement with Adimmune for Japanese Encephalitis Vaccine 27
Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 28
Valneva to Enter into Licensing Agreement with Pharma Company 29
Valneva to Enter into Licensing Agreement with Japan-Based Animal Vaccine Manufacturer 30
GeoVax Labs Enters into Licensing Agreement with Valneva 31
Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine 32
Valneva Raises USD54 Million in Rights Offering 33
Valneva Completes Rights Offering Of Shares For US$53.5 Million 35
Valneva Sells Clinical Manufacturing Operations Facility To Biological E 37
Valneva Acquires Crucell Sweden for USD54 Million 38
Valneva SE, Key Competitors 39
Valneva SE, Key Employees 40
Valneva SE, Other Locations 41
Valneva SE, Subsidiaries 41

List Of Figures


Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Valneva SE, Medical Devices Deals, 2012 to YTD 2018 10

Valneva SE (VLA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Valneva SE (Valneva) is a biotech company that develops lifesaving vaccines. The companys products include IXIARO, a vaccine indicated for the prevention of Japanese encephalitis; and Dukoral, a vaccine indicated

USD 250 View Report

Valneva SE - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Valneva SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Valneva SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports

USD 350 View Report

Valneva SE - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Valneva SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Valneva SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports

USD 350 View Report

Valneva SE - Mergers and Acquisitions (M&A), Partnerships and Alliances and Investment Report

Valneva SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Valneva SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports

USD 350 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available